SPRY2 and prostate carcinoma: Levels of SPRY2 and IL6 showed a significant inverse correlation in ADT‐treated prostate cancer patients with evidence of biochemical relapse (r = −0.427; P = 0.0261; n = 27; Fig EV4E).